Aldosterone

As a core steroid hormone regulating water-salt metabolism and blood pressure homeostasis, aldosterone drugs belong to mineralocorticoid receptor agonists. They specifically bind to mineralocorticoid receptors in renal tubular epithelial cells to promote sodium reabsorption and potassium excretion, maintaining the body's electrolyte balance and stable blood volume. Clinically, they are mainly used for replacement therapy of primary hypoaldosteronism and adrenocortical insufficiency, and can also be used as an auxiliary symptomatic intervention for refractory hypotension. The applicable population covers patients with congenital adrenal dysplasia, patients requiring hormone supplementation after adrenalectomy, etc.

At present, the global market size of aldosterone drugs is approximately USD 180 million, with a compound annual growth rate maintained at around 4.2%. The growth momentum mainly comes from the improvement of the diagnosis rate of rare diseases and the steady release of demand for endocrine replacement therapy. The domestic market is dominated by generic drug supply, and the overall competitive landscape is relatively concentrated, with the top 3 enterprises accounting for more than 70% of the market share. Due to the relatively niche clinical demand, it has not been included in the scope of national centralized volume-based procurement, and product prices have remained stable for a long time.

The original research enterprise of aldosterone is Pfizer, and the original research trade name is Florinef (fludrocortisone, a synthetic analog of aldosterone, a commonly used clinical dosage form to replace natural aldosterone). The core compound patent expired globally in 1995. At present, the mainstream marketed dosage form is 0.1mg oral tablet, which has been included in the FDA Orange Book Reference Listed Drug Catalog, and is also included in the *List of Chemical Drugs* of China. There is no valid A-status registration number for natural aldosterone API in China, and all the approved marketed preparations are fludrocortisone tablets. At present, generic drugs from 3 domestic enterprises have passed the consistency evaluation. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO can provide a full set of impurity reference standards for aldosterone API. Most products support spot supply. Spot orders paid before 16:00 can be shipped on the same day. All products meet the regulatory requirements of multiple regions such as the Chinese Pharmacopoeia and FDA, and can fully meet the compliance needs of various R&D and production scenarios such as impurity research, quality standard establishment, and generic drug consistency evaluation.